Tonix Pharmaceuticals has received US Food Drug and Administration (FDA) approval to initiate a comparative pharmacokinetic and bioavailability study of TNX-102, an oral formulation of cyclobenzaprine for the treatment of fibromyalgia.

TNX-102 is a gelcap containing very low dose cyclobenzaprine, designed for faster and improved absorption relative to conventional cyclobenzaprine products.

About 30 healthy adult volunteers will be enrolled in the single-dose, open-label, randomised and three-way crossover study, which will compare a TNX-102 candidate gelcap containing 2.4mg of cyclobenzaprine to a 5mg cyclobenzaprine tablet.

Additionally, the study will assess the effect of food on the pharmacokinetic profile of TNX-102 in subjects who are either fasting or fed with a high-fat, high-calorie breakfast.

Tonix chairman and president Seth Lederman said that if the study validates the company’s hypothesis, it would proceed with the first of two pivotal clinical trials.

"Our goal is to develop a bedtime cyclobenzaprine treatment with more predictable beneficial effects and possibly reduced next day drowsiness," Lederman said.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.